Progression-free survival results from BOLERO-1 trial

Impact of adding bevacizumab to presurgery chemo for triple-negative breast cancer varies with subtype

Best of ASH 2014

ASH 2014: Highlights in CLL from ASH 2014

Ibrutinib as a single agent and in combination with dexamethasone showed anti-tumour activity in multiple myeloma

Hope for avoiding chemo in patients with Hodgkins lymphoma

ASH 2014: Highlights in mantle cell lymphoma

ASH 2014: Highlights in multiple myeloma

Chemo-free treatment approach demonstrates positive responses in leukaemia patients

Blinatumomab demonstrates significant clinical activity in residual ALL

New immunotherapy compound effective, safe in ALL patients with minimal residual disease

T cell therapy leading to prolonged remission for children with aggressive leukaemia